Atherosclerosis in subjects newly diagnosed with human immunodeficiency virus infection

Tatiana V. Kirichenko, Veronika A. Myasoedova, Tatiana E. Shimonova, Alexandra A. Melnichenko, Dmitri Sviridov, Igor A. Sobenin, Alexey I. Mazus, Alexander N. Orekhov, Michael I. Bukrinsky

Research output: Contribution to journalArticle

Abstract

HIV infection is associated with the increased risk of cardiovascular disease (CVD), even in patients successfully treated with the combination antiretroviral therapy (cART). However, the relationship between HIV, cART, and pathogenesis of CVD remains controversial. In the present study, we evaluated the carotid intima–media thickness (CIMT), a surrogate marker of atherosclerosis, in HIV-infected subjects receiving or not receiving cART. One hundred nine newly diagnosed HIV-infected subjects and one hundred nine uninfected age-matched controls (all males) without the history of CVD, hypertension, or diabetes were recruited into the present study. Cross-sectional analysis at baseline (BL) showed significantly increased levels of triglycerides (TG) and decreased levels of high-density lipoprotein (HDL) in HIV-infected subjects, indicating that these risk factors for CVD appeared during the undiagnosed period of HIV infection. Nevertheless, no differences in CIMT were detected between the groups, suggesting that these risk factors were yet to be translated into the clinical disease. The prospective arm of the study, which included 37 HIV-infected and 23 uninfected subjects, showed higher CIMT increase in HIV-infected group than in control group (P=0.0063). This difference was significant for both cART-treated (P=0.0066) and untreated (P=0.0246) subgroups relative to the uninfected subjects, but no difference was found between the HIV-infected subgroups. These results suggest that cART does not reverse the HIV-induced increase of CIMT. The present study demonstrates that the progression of atherosclerosis is accelerated in HIV-infected subjects regardless of treatment.

Original languageEnglish
Article numberBSR20180597
JournalBioscience Reports
Volume38
Issue number4
DOIs
Publication statusPublished - Jul 18 2018

Fingerprint

Virus Diseases
Viruses
Atherosclerosis
HIV
Cardiovascular Diseases
HDL Lipoproteins
Medical problems
HIV Infections
Triglycerides
Therapeutics
Cross-Sectional Studies
Biomarkers
History
Prospective Studies
Hypertension
Control Groups

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Kirichenko, T. V., Myasoedova, V. A., Shimonova, T. E., Melnichenko, A. A., Sviridov, D., Sobenin, I. A., ... Bukrinsky, M. I. (2018). Atherosclerosis in subjects newly diagnosed with human immunodeficiency virus infection. Bioscience Reports, 38(4), [BSR20180597]. https://doi.org/10.1042/BSR20180597

Atherosclerosis in subjects newly diagnosed with human immunodeficiency virus infection. / Kirichenko, Tatiana V.; Myasoedova, Veronika A.; Shimonova, Tatiana E.; Melnichenko, Alexandra A.; Sviridov, Dmitri; Sobenin, Igor A.; Mazus, Alexey I.; Orekhov, Alexander N.; Bukrinsky, Michael I.

In: Bioscience Reports, Vol. 38, No. 4, BSR20180597, 18.07.2018.

Research output: Contribution to journalArticle

Kirichenko, TV, Myasoedova, VA, Shimonova, TE, Melnichenko, AA, Sviridov, D, Sobenin, IA, Mazus, AI, Orekhov, AN & Bukrinsky, MI 2018, 'Atherosclerosis in subjects newly diagnosed with human immunodeficiency virus infection', Bioscience Reports, vol. 38, no. 4, BSR20180597. https://doi.org/10.1042/BSR20180597
Kirichenko TV, Myasoedova VA, Shimonova TE, Melnichenko AA, Sviridov D, Sobenin IA et al. Atherosclerosis in subjects newly diagnosed with human immunodeficiency virus infection. Bioscience Reports. 2018 Jul 18;38(4). BSR20180597. https://doi.org/10.1042/BSR20180597
Kirichenko, Tatiana V. ; Myasoedova, Veronika A. ; Shimonova, Tatiana E. ; Melnichenko, Alexandra A. ; Sviridov, Dmitri ; Sobenin, Igor A. ; Mazus, Alexey I. ; Orekhov, Alexander N. ; Bukrinsky, Michael I. / Atherosclerosis in subjects newly diagnosed with human immunodeficiency virus infection. In: Bioscience Reports. 2018 ; Vol. 38, No. 4.
@article{14eb3b18fcdd46c681f3c2742126ac44,
title = "Atherosclerosis in subjects newly diagnosed with human immunodeficiency virus infection",
abstract = "HIV infection is associated with the increased risk of cardiovascular disease (CVD), even in patients successfully treated with the combination antiretroviral therapy (cART). However, the relationship between HIV, cART, and pathogenesis of CVD remains controversial. In the present study, we evaluated the carotid intima–media thickness (CIMT), a surrogate marker of atherosclerosis, in HIV-infected subjects receiving or not receiving cART. One hundred nine newly diagnosed HIV-infected subjects and one hundred nine uninfected age-matched controls (all males) without the history of CVD, hypertension, or diabetes were recruited into the present study. Cross-sectional analysis at baseline (BL) showed significantly increased levels of triglycerides (TG) and decreased levels of high-density lipoprotein (HDL) in HIV-infected subjects, indicating that these risk factors for CVD appeared during the undiagnosed period of HIV infection. Nevertheless, no differences in CIMT were detected between the groups, suggesting that these risk factors were yet to be translated into the clinical disease. The prospective arm of the study, which included 37 HIV-infected and 23 uninfected subjects, showed higher CIMT increase in HIV-infected group than in control group (P=0.0063). This difference was significant for both cART-treated (P=0.0066) and untreated (P=0.0246) subgroups relative to the uninfected subjects, but no difference was found between the HIV-infected subgroups. These results suggest that cART does not reverse the HIV-induced increase of CIMT. The present study demonstrates that the progression of atherosclerosis is accelerated in HIV-infected subjects regardless of treatment.",
author = "Kirichenko, {Tatiana V.} and Myasoedova, {Veronika A.} and Shimonova, {Tatiana E.} and Melnichenko, {Alexandra A.} and Dmitri Sviridov and Sobenin, {Igor A.} and Mazus, {Alexey I.} and Orekhov, {Alexander N.} and Bukrinsky, {Michael I.}",
year = "2018",
month = "7",
day = "18",
doi = "10.1042/BSR20180597",
language = "English",
volume = "38",
journal = "Bioscience Reports",
issn = "0144-8463",
publisher = "Portland Press Ltd.",
number = "4",

}

TY - JOUR

T1 - Atherosclerosis in subjects newly diagnosed with human immunodeficiency virus infection

AU - Kirichenko, Tatiana V.

AU - Myasoedova, Veronika A.

AU - Shimonova, Tatiana E.

AU - Melnichenko, Alexandra A.

AU - Sviridov, Dmitri

AU - Sobenin, Igor A.

AU - Mazus, Alexey I.

AU - Orekhov, Alexander N.

AU - Bukrinsky, Michael I.

PY - 2018/7/18

Y1 - 2018/7/18

N2 - HIV infection is associated with the increased risk of cardiovascular disease (CVD), even in patients successfully treated with the combination antiretroviral therapy (cART). However, the relationship between HIV, cART, and pathogenesis of CVD remains controversial. In the present study, we evaluated the carotid intima–media thickness (CIMT), a surrogate marker of atherosclerosis, in HIV-infected subjects receiving or not receiving cART. One hundred nine newly diagnosed HIV-infected subjects and one hundred nine uninfected age-matched controls (all males) without the history of CVD, hypertension, or diabetes were recruited into the present study. Cross-sectional analysis at baseline (BL) showed significantly increased levels of triglycerides (TG) and decreased levels of high-density lipoprotein (HDL) in HIV-infected subjects, indicating that these risk factors for CVD appeared during the undiagnosed period of HIV infection. Nevertheless, no differences in CIMT were detected between the groups, suggesting that these risk factors were yet to be translated into the clinical disease. The prospective arm of the study, which included 37 HIV-infected and 23 uninfected subjects, showed higher CIMT increase in HIV-infected group than in control group (P=0.0063). This difference was significant for both cART-treated (P=0.0066) and untreated (P=0.0246) subgroups relative to the uninfected subjects, but no difference was found between the HIV-infected subgroups. These results suggest that cART does not reverse the HIV-induced increase of CIMT. The present study demonstrates that the progression of atherosclerosis is accelerated in HIV-infected subjects regardless of treatment.

AB - HIV infection is associated with the increased risk of cardiovascular disease (CVD), even in patients successfully treated with the combination antiretroviral therapy (cART). However, the relationship between HIV, cART, and pathogenesis of CVD remains controversial. In the present study, we evaluated the carotid intima–media thickness (CIMT), a surrogate marker of atherosclerosis, in HIV-infected subjects receiving or not receiving cART. One hundred nine newly diagnosed HIV-infected subjects and one hundred nine uninfected age-matched controls (all males) without the history of CVD, hypertension, or diabetes were recruited into the present study. Cross-sectional analysis at baseline (BL) showed significantly increased levels of triglycerides (TG) and decreased levels of high-density lipoprotein (HDL) in HIV-infected subjects, indicating that these risk factors for CVD appeared during the undiagnosed period of HIV infection. Nevertheless, no differences in CIMT were detected between the groups, suggesting that these risk factors were yet to be translated into the clinical disease. The prospective arm of the study, which included 37 HIV-infected and 23 uninfected subjects, showed higher CIMT increase in HIV-infected group than in control group (P=0.0063). This difference was significant for both cART-treated (P=0.0066) and untreated (P=0.0246) subgroups relative to the uninfected subjects, but no difference was found between the HIV-infected subgroups. These results suggest that cART does not reverse the HIV-induced increase of CIMT. The present study demonstrates that the progression of atherosclerosis is accelerated in HIV-infected subjects regardless of treatment.

UR - http://www.scopus.com/inward/record.url?scp=85050151825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050151825&partnerID=8YFLogxK

U2 - 10.1042/BSR20180597

DO - 10.1042/BSR20180597

M3 - Article

VL - 38

JO - Bioscience Reports

JF - Bioscience Reports

SN - 0144-8463

IS - 4

M1 - BSR20180597

ER -